Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02732275 · ClinicalTrials.gov registry record · Phase 1

DS-3201b in Participants With Lymphomas

A Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant, sponsored by Daiichi Sankyo Co..

Active
Registry status
Phase 1
Development phase
100
Enrollment target
20
Study locations

NCT02732275 is a Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant that is active but no longer recruiting, run by Daiichi Sankyo Co.. The registered enrollment target is 100 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02732275, a Phase 1 study of Non-Hodgkin Lymphoma and Lymphoma, Malignant, is active but no longer recruiting, sponsored by Daiichi Sankyo Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL

Conditions Studied

Non-Hodgkin Lymphoma Lymphoma, Malignant

Interventions

  • DRUG DS-3201b

Study Locations (20)

New York

  • Weill Cornell Medicine - New York
  • Memorial Sloan Kettering Cancer Center - New York

Kagoshima-ken

  • Imamura General Hospital - Kagoshima
  • Kagoshima University Hospital - Kagoshima

California

  • City of Hope National Medical center - Duarte

Connecticut

  • Yale University - New Haven

Georgia

  • Emory University - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New Jersey

  • Hackensack University Medical Center - Hackensack

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2016-03-31
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Daiichi Sankyo Co.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02732275

The ClinicalTrials.gov registry entry for NCT02732275 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (34% lower). The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which DS-3201b is the first listed.

NCT02732275 reports 20 study locations spanning 18 distinct geographic areas - top geographies include New York, Kagoshima-ken, California.

Frequently Asked Questions

What is clinical trial NCT02732275 about?

NCT02732275 is a clinical study titled "DS-3201b in Participants With Lymphomas". DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is d...

What is the current status of trial NCT02732275?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2016-03-31. Estimated completion is 2026-12-31.

What conditions does trial NCT02732275 study?

This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Lymphoma, Malignant.

What interventions are being tested in trial NCT02732275?

The interventions under investigation include: DS-3201b (DRUG).

Who is sponsoring clinical trial NCT02732275?

This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02732275 being conducted?

This trial has 20 study locations across California, Connecticut, Georgia, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Hodgkin Lymphoma

All registered trials for this condition

Lymphoma, Malignant

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.